Results of Single Center Study on Delcath’s PHP Therapy Published in Cancer Imaging

by NASDAQ Market News July 22, 2019

NASDAQ Market News
Click here to email author

Salarius Pharmaceuticals Enrolls First Patient in a Phase 1 Clinical Study of its Novel Inhibitor Targeting Epigenetics in Patients with Advanced Solid Tumors

Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients

Ads